July 28, 2020 IntegriChain Supports 72% of YTD 2020 Life Sciences Launches IntegriChain's ICyte Platform, the leading launch readiness platform for Market Access data, advisory, and managed services, has supported 72% of NDA and BLA launches so far this year. Life Sciences manufacturers of all size and complexity rely on the ICyte market access and commercialization platform, offering world-class channel and patient data aggregation and stewardship, the largest offering of contracts and pricing managed services to stand up their business infrastructure, gross-to-net forecasting and accrual systems, and launch and pricing transparency advisory.
July 22, 2020 IntegriChain Summer Release Advances Patient Data Insights and Actionability of Industry-Leading ICyte Access Platform IntegriChain launches the summer release of its ICyte Platform of access data and analytics solutions. The release delivers a new Data Quality Cockpit, employing data science advancements and new integrations that detect patient data quality issues in near real time and improve patient access to critical therapies at specialty pharmacies.
June 25, 2020 IntegriChain Appoints Experienced Product Leader to Guide Data Products and Analytics Platform IntegriChain appoints Dharma Subramanian, a seasoned product leader, as Vice President, Data Products and ICyte Analytics. Subramanian delivers more than 15 years of product management and leadership including roles at Reltio, Veeva Systems, IBM, and Unisys. At IntegriChain, he will be responsible for the company’s channel and patient data and analytics products as well as the unified ICyte access data and business process platform.
June 24, 2020 CEO Council for Growth and IntegriChain Sponsor Educational Webinar Series for Emerging Cell and Gene Therapy Companies IntegriChain and the Chamber of Commerce for Greater Philadelphia’s regional CEO Council for Growth’s Cell & Gene Therapy and Connected Health Initiative will offer a complimentary educational series for emerging cell and gene therapy companies. Focused on launch and commercial readiness, the three-part webinar series begins on Thursday, June 25.
May 18, 2020 IntegriChain Featured in Gartner’s Market Guide for Revenue Management IntegriChain is prominently featured in Gartner’s new Market Guide for Revenue Management in Pharmaceuticals and Biotechnology, which is available here from the Gartner.com website. Following IntegriChain’s acquisition of the Life Sciences Division of Cumberland last month, the report highlights the combined company’s flexible and agile revenue management data, analytics, and managed services platform.
April 21, 2020 IntegriChain Appoints Experienced HR Leader Vickie Kozhushchenko as SVP, People and Culture IntegriChain has appointed a highly seasoned human resources executive as Senior Vice President of People and Culture. Vickie Kozhushchenko delivers more than 20 years of global HR experience, including senior executive roles at Clean Earth, Aramark, Turner Broadcasting System, Comcast and Coordinated Health and extensive acquisition integration experience. She is responsible for IntegriChain’s global HR organization, including the organization’s team development, recruiting and retention programs and policy.
April 13, 2020 IntegriChain Acquires the Life Sciences Division of Cumberland, Creating the Largest Data and Business Process Platform for Market Access and Commercialization of Specialty, Precision, and Retail Pharmaceuticals IntegriChain has acquired Cumberland’s Life Science Division, a leading provider of managed services, advisory services and systems integration for contracts, pricing and revenue management. With this acquisition, IntegriChain delivers the Life Science industry’s most comprehensive and scalable data and business process platform for commercialization and market access of cell and gene therapy, specialty, and retail pharmaceuticals.
January 8, 2020 IntegriChain Supported 65+ Life Sciences Launches in Last 36 Months IntegriChain today announced that the company has supported more than 65 launches of innovative therapies including cell and gene therapy (CGT) and orphan & rare diseases (ORD) during the last three years. Emerging Life Sciences manufacturers have engaged IntegriChain for its best-in-class comprehensive commercialization platform, including channel and patient data stewardship and managed services to stand up their business infrastructure for all aspects of patient access: contracts and pricing, gross-to-net, channel, and patient services.
December 3, 2019 IntegriChain Implements Data-Science-Driven Stewardship of Specialty Pharmacy Data for Multiple Top-30 Life Sciences Manufacturers IntegriChain announced that multiple top-30 Life Sciences manufacturers have implemented its stewardship and refining solutions to improve the quality and actionability of specialty pharmacy data. These solutions, based on recent data science advancements in the ICyte Platform, overcome the industry challenge of immature patient data sets that includes non-standardize data from hundreds of data suppliers delivered with varied quality. IntegriChain Co-Founder and EVP Josh Halpern will present more on this topic during his presentation, “The State of Patient Status Visibility and the Use of Artificial Intelligence to Drive Specialty Channel Insights,” at CBI Trade & Channel, beginning today in Philadelphia.
November 12, 2019 IntegriChain Gross-to-Net Automation Goes Live with Akcea Therapeutics IntegriChain completes implementation of its Gross-to-Net (GTN) Managed Services with Akcea Therapeutics. IntegriChain GTN Solutions, which are built to industry best practices and are scalable and auditable, deliver end-to-end revenue management for Life Sciences Market Access and Finance teams that improves forecast accuracy, GTN modeling, and financial close efficiency. IntegriChain also is finalizing the implementation-readiness process for five additional GTN Managed Services customers.
